Tiziana Life Sciences (TILS)

 

Latest News

Second Price Monitoring Extn

RNS Number: 0882P Tiziana Life Sciences PLC 23 May 2018 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined...

Price Monitoring Extension

RNS Number: 0876P Tiziana Life Sciences PLC 23 May 2018 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the executi...

Tiziana Life Sciences gets positive drug tolerability evaluation

Tiziana Life Sciences, which is developing drugs targeting cancer and inflammatory diseases, said it had received a positive...

Milciclib Phase 2a Trial - Tolerability Update

RNS Number: 1999O Tiziana Life Sciences PLC 16 May 2018 Tiziana Life Sciences plc ("Tiziana" or the "Company") Tiziana Life Sciences Announces Interim Analysis Data from an Ongoing Phase 2a Trial of Milciclib Safety and Tolerability in Sorafenib-refractory or -intolerable, Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Patients Treatment with ...

All News

DateHeadlineSource
23-05-18Second Price Monitoring ExtnRNS
23-05-18Price Monitoring ExtensionRNS
16-05-18Tiziana Life Sciences gets positive drug tolerability evaluationStockMarketWire
16-05-18Milciclib Phase 2a Trial - Tolerability UpdateRNS
01-05-18Grant of Options - Director DealingRNS
27-04-18Issue of EquityRNS
19-04-18Tiziana raises £825,000StockMarketWire
19-04-18SubscriptionRNS
16-04-18License AgreementRNS
09-04-18Presentation at ASCO 3 June 2018RNS
05-04-18Appointment of BrokerRNS
04-04-18Appointment of DirectorRNS
05-03-18Placing to raise ?600,000 and issue of equityRNS
02-03-18Statement re brokerRNS
22-01-18Tiziana Life Sciences completes share placementStockMarketWire
22-01-18PlacingRNS
16-01-18Tiziana Life Sciences places news sharesStockMarketWire
16-01-18PlacingRNS
15-12-17Placing and Issue of EquityRNS
08-12-17Tiziana Life Sciences says cancer drug well-toleratedStockMarketWire
08-12-17Milciclib Phase 2a Trial UpdateRNS
27-11-17Tiziana Life Sciences issues sharesStockMarketWire
27-11-17PlacingRNS
23-11-17Tiziana rare cancer drug meets endpointsStockMarketWire
23-11-17Phase II Clinical Trial UpdateRNS
20-11-17Tiziana Life Sciences completes share issueStockMarketWire
20-11-17SubscriptionRNS
29-09-17Interim Results for Six Months Ended 30 June 2017RNS
06-09-17Tiziana says development of oral formulation of foralumab to be used in clinical studiesStockMarketWire
06-09-17A Proprietary Oral Formulation of ForalumabRNS
31-08-17Grant of options - Director's dealingRNS
16-08-17Tiziana converts loan notes to sharesStockMarketWire
16-08-17Conversion of outstanding loan notesRNS
28-07-17Publication of Research Article on ForalumabRNS
19-07-17Tiziana enrols first patient in Phase IIa clinical trialStockMarketWire
19-07-17Initiation of a Phase IIa Clinical TrialRNS
12-07-17Proposed changes to CLNs and Warrant TermsRNS
29-06-17Result of AGMRNS
12-06-17Appointment of Dr Kunwar Shailubhai as CEORNS
08-06-17NOTIFICATION OF MAJOR INTEREST IN SHARESRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory